Themis Medicare Limited has informed the Exchange about Investor Presentation
THEMISMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Themis Medicare reported Q3 FY26 consolidated revenue of ₹90.13 crore, down 3.9% year-on-year, but profitability improved sharply with EBITDA at ₹9.80 crore (up 14.9% YoY) and PAT at ₹10.09 crore versus ₹0.52 crore last year. EBITDA margin expanded by 178 basis points to 10.87%, aided by cost rationalization despite softness in the formulations business. The API segment more than doubled YoY in the quarter, while the hospital and trade businesses also improved. However, the 9-month picture remains weak with revenue down 20.4% YoY at ₹265.71 crore and the company slipping into a loss (PAT of -₹7.74 crore). Management highlighted that a regulatory matter affecting a significant business line is under review and a positive development is expected soon. The company is targeting leadership in India's hospital business with phased expansion into CIS, Latin America, and GCC markets (0-3 years), followed by regulated markets like EU and USA (3-5 years).
Near-term, the stock may react positively to the strong Q3 margin recovery and return to profitability after several weak quarters, but the unresolved regulatory disruption and 9-month loss keep caution warranted. Investors should watch for an update on the regulatory matter and signs of sustained margin improvement beyond Q3.